<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03083587</url>
  </required_header>
  <id_info>
    <org_study_id>2016/1768</org_study_id>
    <nct_id>NCT03083587</nct_id>
  </id_info>
  <brief_title>Frequent Activity Snacks Breaks</brief_title>
  <acronym>FABS</acronym>
  <official_title>Frequent Activity Snacks Breaks - Interrupting Sedentary Behaviour</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Baker IDI Heart and Diabetes Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Australian Catholic University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stockholm County Council, Sweden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is a growing health burden in Sweden and Europe arising from the interrelated sequelae
      of metabolic disorders comprising impaired glucose tolerance (IGT), obesity and T2DM. Obesity
      and inactivity are the main drivers of IGT and T2DM and are responsible for up to 8% of
      health costs and 13% of deaths in Europe, with the risk of co-morbidities rising in parallel
      with increasing body weight. IGT and T2DM are the paradigm of inactivity-related disorders:
      the majority of people who have IGT or T2DM are overweight and inactive, with up to 80% being
      obese. A recent meta-analysis of 42 studies concluded that sedentary time was independently
      associated with a greater risk of T2D, all-cause mortality, cardiovascular disease incidence
      and mortality, and cancer incidence and mortality (breast, colon, colorectal, endometrial and
      epithelial ovarian cancers) (Ann Intern Med. 2015;162:123-32). A recent systematic review of
      trials published up to April 2014 identified 16 separate studies and concluded that there is
      considerable evidence of the positive effects of breaking up prolonged sitting time with
      light-intensity ambulatory physical activity and standing on postprandial metabolic
      parameters, including glucose, insulin and triglyceride levels (Med Sci Sports Exerc.
      2015:47:2053-61). However, to date, all of the published experimental trials describing the
      beneficial effects of breaking up sitting time on metabolic risk markers have been restricted
      to acute exposure periods (1-5 days). We will perform a RCT intervention study, which
      examines the efficacy (clinically relevant responses) and practical implementation of
      low-impact training in sedentary obese individuals during the day.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in metabolic health including insulin resistance</measure>
    <time_frame>Change from baseline and 4 week intervention</time_frame>
    <description>Oral glucose tolerance test including baseline glucose and insulin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes at the molecular level in skeletal and fat muscle biopsies</measure>
    <time_frame>Change from baseline and 4 week intervention</time_frame>
    <description>insulin signalling cascade, the pathways that regulate protein synthesis and atrophy, as well as the content and function of mitochondria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes at the molecular level in skeletal and fat muscle biopsies</measure>
    <time_frame>Change from baseline and 4 week intervention</time_frame>
    <description>The pathways that regulate protein synthesis and atrophy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes at the molecular level in skeletal and fat muscle biopsies</measure>
    <time_frame>Change from baseline and 4 week intervention</time_frame>
    <description>Lipid, protein and metabolites</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in gene expression</measure>
    <time_frame>Change from baseline and 4 week intervention</time_frame>
    <description>RNA, mRNA, DNA methylation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in physical activity</measure>
    <time_frame>Change from baseline and 4 week intervention</time_frame>
    <description>Objective measures of standing and sitting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in plasma glucose</measure>
    <time_frame>Change from baseline and 4 week intervention</time_frame>
    <description>Continuous glucose monitoring</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Obesity</condition>
  <condition>Insulin Resistance</condition>
  <condition>Sedentary Lifestyle</condition>
  <arm_group>
    <arm_group_label>No intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Normal lifestyle. Subjects will undergo a muscle and fat biopsy at the start of the 4 w period and after. An oral glucose test at the start and after completion of the 4 week period. Physical activity and glucose will be monitored during the study period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exercise intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Followed by a 1 week normal run in period subjects will undergo a 3 min bout, every half hour between 8 am and 6 pm comprises of simple low-intensity exercise such as moderate walking about or climbing a flight of stairs over a 3-week period. Subjects will undergo a muscle and fat biopsy at the start of the 4 w period and after. An oral glucose test at the start and after completion of the 4 week period. Physical activity and glucose will be monitored during the study period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Normal lifestyle</intervention_name>
    <description>Normal lifestyle</description>
    <arm_group_label>No intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Exercise</intervention_name>
    <description>Mild exercise 3 min every half hour</description>
    <arm_group_label>Exercise intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>muscle and fat biopsy</intervention_name>
    <description>Biopsy under local anesthesia</description>
    <arm_group_label>No intervention</arm_group_label>
    <arm_group_label>Exercise intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Continuous glucose monitoring</intervention_name>
    <description>Glucose concentrations during the study period</description>
    <arm_group_label>No intervention</arm_group_label>
    <arm_group_label>Exercise intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Activity monitoring (ActivePal)</intervention_name>
    <description>Objective measurements of standing and sitting time</description>
    <arm_group_label>No intervention</arm_group_label>
    <arm_group_label>Exercise intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Sedentary lifestyle,

          -  BMI 30-40 kg/m2

        Exclusion Criteria:

          -  Unable to read Swedish (for informed consent),

          -  anticoagulant therapy,

          -  unability to perform intervention
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erik Naslund, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Erik Naslund, MD, PhD</last_name>
    <email>Erik.Naslund@ki.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>Danderyd Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>182 88</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erik Naslund, MD, PhD</last_name>
      <email>Erik.Naslund@ki.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 3, 2017</study_first_submitted>
  <study_first_submitted_qc>March 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 20, 2017</study_first_posted>
  <last_update_submitted>April 5, 2017</last_update_submitted>
  <last_update_submitted_qc>April 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Erik NÃ¤slund</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

